This inventor holds 3 USPTO granted patents. Top assignees: Kyowa Hakko Kogyo Co., Ltd., Kyowa Hakko Kirin Co., Limited. Active years: 2009-2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2009-2010
Title: Jiro Kajita: Innovator in Hsp90 Family Protein Inhibitors
Introduction
Jiro Kajita is a notable inventor based in Sunto-gun, Japan. He has made significant contributions to the field of biochemistry, particularly in the development of Hsp90 family protein inhibitors. With a total of 3 patents to his name, Kajita's work has the potential to impact therapeutic approaches in various medical conditions.
Latest Patents
Kajita's latest patents focus on Hsp90 family protein inhibitors. These inventions provide a benzoyl compound as an active ingredient, represented by a specific general formula. The compounds are designed to include various substituents, allowing for a range of applications in pharmaceutical formulations. The patents also cover prodrugs and pharmaceutically acceptable salts of these benzoyl compounds, showcasing the versatility and potential of his innovations.
Career Highlights
Throughout his career, Jiro Kajita has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Kyowa Hakko Kogyo Co., Ltd. and Kyowa Hakko Kirin Co., Limited. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Kajita has collaborated with esteemed colleagues in his field, including Shinji Nara and Hiroshi Nakagawa. These partnerships have likely enhanced his research and development efforts, leading to the successful creation of his patented inventions.
Conclusion
Jiro Kajita's contributions to the field of biochemistry, particularly through his patents on Hsp90 family protein inhibitors, highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

